Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma

Brentuximab vedotin is a promising antibody–drug conjugate (ADC) targeting CD30 of tumor cells. It selectively delivers monomethyl auristatin E (MMAE) into CD30-expressing cells and induces tumor cell apoptosis. Various clinical trials have provided evidence that it is effective in relapsed or refra...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Runzhe, Chen, Baoan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376183/
https://www.ncbi.nlm.nih.gov/pubmed/25848209
http://dx.doi.org/10.2147/DDDT.S82007
_version_ 1782363699468566528
author Chen, Runzhe
Chen, Baoan
author_facet Chen, Runzhe
Chen, Baoan
author_sort Chen, Runzhe
collection PubMed
description Brentuximab vedotin is a promising antibody–drug conjugate (ADC) targeting CD30 of tumor cells. It selectively delivers monomethyl auristatin E (MMAE) into CD30-expressing cells and induces tumor cell apoptosis. Various clinical trials have provided evidence that it is effective in relapsed or refractory Hodgkin’s lymphoma (HL), and it has also shown its advantages in other CD30-positive lymphomas. In this review, we focus on the structure, mechanisms, and pharmacokinetics of brentuximab vedotin. We also summarize clinical trials with brentuximab vedotin and make recommendations for brentuximab vedotin in the treatment of relapsed or refractory HL.
format Online
Article
Text
id pubmed-4376183
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-43761832015-04-06 Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma Chen, Runzhe Chen, Baoan Drug Des Devel Ther Review Brentuximab vedotin is a promising antibody–drug conjugate (ADC) targeting CD30 of tumor cells. It selectively delivers monomethyl auristatin E (MMAE) into CD30-expressing cells and induces tumor cell apoptosis. Various clinical trials have provided evidence that it is effective in relapsed or refractory Hodgkin’s lymphoma (HL), and it has also shown its advantages in other CD30-positive lymphomas. In this review, we focus on the structure, mechanisms, and pharmacokinetics of brentuximab vedotin. We also summarize clinical trials with brentuximab vedotin and make recommendations for brentuximab vedotin in the treatment of relapsed or refractory HL. Dove Medical Press 2015-03-23 /pmc/articles/PMC4376183/ /pubmed/25848209 http://dx.doi.org/10.2147/DDDT.S82007 Text en © 2015 Chen and Chen. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Chen, Runzhe
Chen, Baoan
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
title Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
title_full Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
title_fullStr Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
title_full_unstemmed Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
title_short Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
title_sort brentuximab vedotin for relapsed or refractory hodgkin’s lymphoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376183/
https://www.ncbi.nlm.nih.gov/pubmed/25848209
http://dx.doi.org/10.2147/DDDT.S82007
work_keys_str_mv AT chenrunzhe brentuximabvedotinforrelapsedorrefractoryhodgkinslymphoma
AT chenbaoan brentuximabvedotinforrelapsedorrefractoryhodgkinslymphoma

Ejemplares similares